Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Dr Reddys unveils...

    Dr Reddys unveils generic Deferasirox Tablets in US

    Farhat NasimWritten by Farhat Nasim Published On 2019-12-10T12:53:01+05:30  |  Updated On 10 Dec 2019 12:53 PM IST

    The two different products launched by Dr Reddy's Labs in the US market are generic versions of Exjade (deferasirox) and Jadenu (deferasirox) indicated to treat iron overload caused by blood transfusions in adults and children at least 2 years old.


    New Delhi: Hyderabad-based Dr Reddys Laboratories (Dr Reddys) recently announced the launch of Deferasirox Tablets for Oral Suspension and Deferasirox Film-Coated Tablets in the US market.


    Deferasirox Tablets for Oral Suspension is a therapeutically equivalent generic version of Exjade (deferasirox) Tablets for Oral Suspension, approved by the U. S. Food and Drug Administration (USFDA) while Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Jadenu (deferasirox) Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the US health regulator.


    Deferasirox is used to treat iron overload caused by blood transfusions in adults and children at least 2 years old. Deferasirox is also used to treat chronic iron overload syndrome caused by a genetic blood disorder in adults and children who are at least 10 years old.


    Also Read: Dr Reddys launches a generic version of Hemabate injection indicated for abortion in the US


    The Exjade brand had the US sales of approximately $113 million MAT and Jadenu brand had US sales of approximately $470 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health.


    Dr Reddys Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths in bottle count sizes of 30 and Deferasirox Film-Coated Tablets are available in 90 mg and 360 mg dosage strengths in bottle count
    sizes of 30.


    Also Read: Dr Reddys unveils cancer drug Bortezomib in the US

    blood transfusionDeferasiroxDr Reddy'sDr Reddy's LaboratoriesDr Reddy's Labsdrug launchExjadeiron overload syndromeJadenuOral Suspensionpharmapharma newspharma news indiaUSFDA

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok